期刊
ONCOGENE
卷 28, 期 16, 页码 1843-1852出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2009.33
关键词
RAP80; breast cancer; BRCA1; ubiquitin
资金
- Finnish Breast Cancer Group
- Cancer Foundation of Northern Finland
- Orion-Farmos Research Foundation
- Academy of Finland
- Finnish Cancer Society
- Foundation for the Finnish Cancer Institute and the Sigrid Juselius Foundation
- NIH [T32-GM-007229]
- National Cancer Institute [1K08CA106597-01]
- Sidney Kimmel Foundation Scholar Award
- Mary Kay Ash Charitable Foundation Cancer Research
- Abramson Family Cancer Research Institute
Germline mutations in two major susceptibility genes, BRCA1 and BRCA2, account for nearly 20% of familial breast cancers. A majority of the remaining genetic factors involved in heritable breast cancer susceptibility are, however, unknown. Recently, a new BRCA1-interacting protein, receptor associated protein 80 (RAP80), was identified. RAP80 plays an important role in BRCA1-mediated DNA damage responses (DDRs) by recruiting BRCA1 to DNA double-strand breaks (DSBs). A comprehensive screening of DNA from affected index cases of 112 BRCA1/BRCA2 mutation-negative Finnish breast cancer families revealed altogether 10 alterations in RAP80, one of which, c.241-243delGAA, resulted in a single glutamic acid deletion at residue 81 in a highly conserved region of ubiquitin interaction motif 1. The resultant delE81 protein product displayed significantly reduced ubiquitin binding and DSB localization. Expression of the RAP80 delE81 allele impaired both BRCA1 and ABRA1 DSB recruitment, thus compromising BRCA1-mediated DDR signaling. Compared with wildtype RAP80, expression of the delE81 allele was associated with a significant increase in cytogenetically detectable chromosomal aberrations, particularly chromatid breaks. Although evidently quite rare, these results suggest that critical constitutional mutations in RAP80 abrogate DDR function and may be involved in genetic predisposition to cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据